JANX
Closed
Janux Therapeutics Inc
23.22
+0.12 (+0.52%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 23.1
Day's Range: 22.74 - 24.725
Send
sign up or login to leave a comment!
When Written:
13.42
Janux Therapeutics Inc. is a biotechnology company that focuses on developing novel cancer therapies. The company is based in San Diego, California, and was founded in 2017. Janux Therapeutics is a subsidiary of the global pharmaceutical company, Merck & Co., Inc.
Janux Therapeutics uses its proprietary platform technology, called the "TRIP" (T cell Redirected Immunomodulatory Protein) platform, to develop cancer immunotherapies. The TRIP platform is designed to engineer T cells to target specific cancer cells and modulate the immune system to enhance anti-tumor activity.
The company's lead product candidate, JTX-1811, is a TRIP-based therapy that is designed to target solid tumors by redirecting T cells to recognize and attack cancer cells. Janux Therapeutics is also developing other TRIP-based therapies for the treatment of various types of cancer.
Janux Therapeutics has received funding from a variety of sources, including venture capital firms and strategic partnerships with other biotech companies. The company's mission is to develop innovative cancer therapies that can improve patient outcomes and ultimately lead to a cure for cancer.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Janux Therapeutics uses its proprietary platform technology, called the "TRIP" (T cell Redirected Immunomodulatory Protein) platform, to develop cancer immunotherapies. The TRIP platform is designed to engineer T cells to target specific cancer cells and modulate the immune system to enhance anti-tumor activity.
The company's lead product candidate, JTX-1811, is a TRIP-based therapy that is designed to target solid tumors by redirecting T cells to recognize and attack cancer cells. Janux Therapeutics is also developing other TRIP-based therapies for the treatment of various types of cancer.
Janux Therapeutics has received funding from a variety of sources, including venture capital firms and strategic partnerships with other biotech companies. The company's mission is to develop innovative cancer therapies that can improve patient outcomes and ultimately lead to a cure for cancer.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








